Based on the content describing a Phase 2 trial combining the oncolytic virus RP1 and the PD-1 inhibitor nivolumab for treatment-resistant melanoma – BIOENGINEER.ORG https://bioengineer.org Bioengineering Fri, 07 Nov 2025 17:09:57 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png Based on the content describing a Phase 2 trial combining the oncolytic virus RP1 and the PD-1 inhibitor nivolumab for treatment-resistant melanoma – BIOENGINEER.ORG https://bioengineer.org 32 32 72741379 Combination Immunotherapy Breaks Through Melanoma Treatment Resistance https://bioengineer.org/combination-immunotherapy-breaks-through-melanoma-treatment-resistance/ Fri, 07 Nov 2025 17:09:50 +0000 https://bioengineer.org/combination-immunotherapy-breaks-through-melanoma-treatment-resistance/ 293328